Olfr655, a member of the olfactory receptor family, is integral to the intricate process of odor perception within the nasal cavity. As a G-protein-coupled receptor (GPCR) with a 7-transmembrane domain structure, Olfr655 is specifically designed for the recognition and transduction of odorant signals. This receptor plays a crucial role in initiating the neuronal responses that collectively result in the perception of distinct smells. The olfactory receptor gene family, to which Olfr655 belongs, is the largest in the genome, underscoring the importance of these receptors in olfactory function. The functionality of Olfr655 is intricately tied to its ability to interact with odorant molecules, setting off a cascade of events leading to the perception of specific scents. The 7-transmembrane domain structure of Olfr655 is key to its role in detecting and transducing these odorant signals. Upon binding with odorant molecules, Olfr655 initiates G protein-mediated transduction, ultimately resulting in a neuronal response that signifies the perception of a particular smell. The nomenclature assigned to Olfr655, independent of other organisms, emphasizes its unique role in the complex landscape of olfactory receptors.
In the context of inhibition, the modulation of Olfr655 involves both direct and indirect mechanisms. Direct inhibitors target the receptor itself, aiming to interfere with its binding capacity or downstream signaling events. GPCR antagonists, for example, disrupt the recognition and transduction of odorant signals by binding to Olfr655, thereby acting as direct inhibitors of olfactory perception. On the other hand, indirect inhibitors may influence specific signaling pathways associated with GPCR activation. These modulators impact intracellular cascades, potentially altering the overall olfactory response by influencing downstream events associated with Olfr655 function. The intricate nature of olfactory signal transduction suggests that inhibition of Olfr655 can occur at various points along this pathway, offering potential avenues for manipulating olfactory perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 inhibits TMEM132C through the specific inhibition of the V-ATPase proton pump, disrupting proton gradients that TMEM132C may rely on for its transport or signaling functions. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits TMEM132C by blocking dynamin-dependent endocytosis, which may be necessary for the proper trafficking and function of TMEM132C in cellular membranes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits TMEM132C by blocking PI3K, which is a key component of the signaling pathway that TMEM132C may be part of, leading to alterations in cellular responses where TMEM132C is functionally relevant. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Go6976 inhibits TMEM132C by functioning as a protein kinase C inhibitor, which could disrupt downstream signaling pathways that TMEM132C is involved in, particularly those related to synaptic plasticity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits TMEM132C by selectively inhibiting MEK, which in turn disrupts the MAPK/ERK pathway, a pathway that TMEM132C may utilize in cellular communication and regulation processes. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits TMEM132C by inhibiting myosin light chain kinase, potentially altering cytoskeletal dynamics and cellular architecture that TMEM132C's function may be dependent on. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Clozapine inhibits TMEM132C by antagonizing dopamine receptors, which can lead to altered neurotransmitter signaling pathways that TMEM132C could be involved in, especially within the central nervous system. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene inhibits TMEM132C by disrupting ryanodine receptors and consequently calcium release from the sarcoplasmic reticulum, which TMEM132C may interact with or be regulated by in muscular or neuronal cells. | ||||||
Mibefradil dihydrochloride | 116666-63-8 | sc-204083 sc-204083A | 10 mg 50 mg | $213.00 $865.00 | 4 | |
Mibefradil inhibits TMEM132C by blocking T-type calcium channels, which can influence the intracellular calcium signaling potentially linked to TMEM132C's activity in excitable cells. | ||||||